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depression in health and disease: focus on mitogen-activated 
protein kinase pathways 
 
Thomas M. Sanderson, Ellen L. Hogg, Graham L. Collingridge and Sonia A. L. Correa 
 
 
Abstract 
Group I metabotropic glutamate receptor (mGluR) dependent long-term depression (LTD) is a major form of 
synaptic plasticity underlying learning and memory. The molecular mechanisms involved in mGluR-LTD 
have been investigated intensively for the last two decades. In this 60th anniversary special issue article, we 
review the recent advances in determining the mechanisms that regulate the induction, transduction and 
expression of mGluR-LTD in the hippocampus, with a focus on the mitogen-activated protein kinase 
(MAPK) pathways. In particular we discuss the requirement of p38 MAPK and extracellular signal-regulated 
kinase 1/2 activation. The recent advances in understanding the signaling cascades regulating mGluR-LTD are 
then related to the cognitive impairments observed in neurological disorders, such as fragile X syndrome and 
Alzheimer’s disease. 
 
Keywords: Alzheimer’s disease, AMPAR trafﬁcking, ERK1/2, Fragile X syndrome, mGluR-LTD, p38 
mitogen-activated protein kinase. 
 
The hippocampus is an area of the brain that is required for the formation and retrieval of various types of 
memory, including spatial memories in rodents (Neves et al. 2008). The loss of hippocampal function causes 
memory impairment and reduced cognitive ability (Scoville and  Milner 1957;  Moser et al. 1993; Broadbent 
et al. 2004).  The fundamental role the hippocampus plays in memory formation has led to extensive 
investigation of the mechanisms by which the synapses of the hippocampus change, to under- stand the 
neurophysiology that underpins its function. These processes are forms of synaptic plasticity and include 
long-term increases in synaptic strength, termed long-term potentiation (LTP), and long-term decreases in 
synaptic strength, named long-term depression (LTD). These processes, can be induced in many areas of 
the brain, but are extensively studied in the CA1 region of the hippocampus where they are thought to 
underlie spatial learning and memory (Neves et al. 2008). In the hippocampus, LTD can be triggered by the 
activation of N-methyl-D-aspartate receptors (NMDAR) (Collingridge et al. 1983; Fujii et al. 1991; Dudek 
and Bear 1992) or group I metabotropic glutamate receptors (mGluRs) (Palmer et al. 1997; Fitzjohn  et al. 
1999). These two forms of LTD differ in many respects (Collingridge et al. 2010) and in this review we will focus 
on mGluR-LTD. 
 
The role of mGluR-LTD in memory processes is beginning to emerge. mGluR5 knockout (KO) animals 
have impaired mGluR-LTD and show deﬁcits in both acquisition and reversal learning (Lu et al. 1997; Xu et 
al. 2009). However, as mGluR5 inhibition also results in deﬁcits in LTP (Lu et al. 1997; Manahan-
Vaughan and Braunewell 2005) and can dramatically disrupt metaplastic modulation of LTP (Bortolotto et al. 
2005), dissecting the speciﬁc roles that mGluR-LTD play in memory has been challenging. More speciﬁc 
manipulations that are expected to predominantly affect mGluR-LTD have strengthened the case for a role of 
mGluR-LTD in spatial reversal learning (Eales et al. 2014). Novel object recognition has been reported to 
facilitate hippocampal LTD recorded in vivo (Manahan-Vaughan and Braunewell 1999; Kemp and Manahan-
Vaughan 2004) and because this facilitation requires mGluR5 as well as NMDARs (Goh and Manahan-
Vaughan 2013) it is plausible that mGluR-LTD may play a role in this form of learning. This observation is 
strengthened as novel object recognition is impaired in mice where signaling pathways involved in mGluR-
LTD are disrupted (Di Prisco et al. 2014). 
 
The precise mechanisms underlying mGluR-LTD are still under debate, and it is not clear the extent to 
which the depression in synaptic transmission is caused by a decrease in glutamate release from the pre-
synaptic terminal or to changes in the number or properties of the post-synaptic receptors that respond to a 
ﬁxed amount of glutamate release (Watabe et al. 2002; Zakharenko et al. 2002; Gladding et al. 2009b; 
Collingridge et al. 2010). In this review, we will discuss the post-synaptic mechanisms underlying the 
expression of mGluR-LTD with a focus on mitogen-activated protein kinase (MAPK) signaling. We then 
discuss how mGluR-LTD may be involved in neurological disorders, such as fragile X syndrome and 
Alzheimer’s disease. 
 
Molecular mechanisms involved in the induction of mGluR-LTD 
 
mGluR-LTD is most widely studied in the CA1 area of the hippocampus and can be induced by either 
application of a group I mGluR agonist, typically (RS)- or (S)-3,5-dihydroxyphenylglycine (DHPG) (Palmer et 
al. 1997; Fitzjohn et al. 1999), or by physiological activation of synapses (Bashir et al. 1993), typically by 
using paired-pulse low frequency stimulation (Kemp and Bashir 1997; Huber et al. 2000). The expression of 
mGluR-LTD is mediated, in part, by a reduction in the number of a-amino-3-hydroxy-5-methyl-4- 
isoxazolepropionic acid receptors (AMPAR) on the plasma membrane (Carroll et al. 2001; Snyder et al. 
2001; Xiao et al. 2001; Huang et al. 2004; Moult et al. 2006; Gladding et al. 2009a,b; Sanderson et al. 2011; 
Eales et al. 2014). 
 
Group I-mGluRs are composed of mGluR1 and mGluR5, which are both expressed in area CA1 of the 
hippocampus (Shigemoto et al. 1992, 1997; Conquet et al. 1994; Lujan et al. 1996; Berthele et al.1998; 
Ferraguti et al.1998). Both mGluR1 and mGluR5 receptors have been shown to induce mGluR-LTD either 
singly or in combination (Palmer et al. 1997; Fitzjohn et al. 1999; Hou and Klann 2004; Volk et al. 2006; 
Moult et al. 2008; Neyman and Manahan-Vaughan 2008; Nadif Kasri et al. 2011). The variable involvement 
of the two subtypes may reﬂect factors such as differences in the induction protocols, the expression 
mechanism under investigation and the developmental stage of the synapses. 
 
One of the most remarkable discoveries regarding the molecular mechanism regulating mGluR-LTD is the 
observation that the induction of mGluR-LTD requires rapid mRNA translation (Huber et al. 2000). However, 
it is important to note that mGluR-LTD is not invariably dependent on protein translation. Inhibition of 
protein translation did not affect the induction of mGluR-LTD in neonatal animals (Nosyreva and Huber 
2005) and in hippocampal slices obtained from 10 to 15 week animals mGluR-LTD occurred independently 
of protein translation, using either synaptic induction protocols (Moult et al. 2008) or DHPG (Moult, Fitzjohn, 
and Collingridge, unpublished observations). The extent to which mGluR-LTD is dependent on de novo protein 
synthesis remains to be established. 
 
 
 
 
Fig. 1 Steps showing the upstream activation of p38, extracellular signal-regulated kinase 1/2 (ERK1/2), 
and Jun N-terminal kinases (JNK) in neurons. 
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Table 1 Summary of the requirement of p38 and extracellular signal-regulated kinase 1/2 (ERK1/2) during mGluR-LTD in the CA1 area of the hippocampus 
 
 
 
Induction 
 
 
Species 
 
 
Age 
p38 Phos- 
phorylation 
p38 inhibition effect 
on mGluR-LTD 
ERK 1/2 
Phosphorylation 
ERK 1/2 inhibition 
effect on mGluR-
LTD 
 
 
Reference 
Schaffer collateral Sprague–Dawley P4-11 Increased Blocked LTD No effect Not determined Bolshakov et al., 
2000 
LFS (5 Hz stimulation for 3 
min) 
rats   20 lM SB203580    
Schaffer collateral Wistar rats 10–15 weeks Increased Blocked LTD Not determined No effect on LTD Moult et al., 2008 
PP-LFS (900 paired-pulses 
at 1 Hz, 50 ms apart) 
   5 lM SB203580  20 lM U0126  
DHPG Sprague–Dawley P21-30 Increased Blocked LTD Not determined No effect on LTD Huang et al., 2004 
50 lM 
5 min 
rats   1 lM SB203580  50 lM PD98059  
DHPG C57/BL6 mice P0 cultures Increased Blocked LTD Not determined Not determined Eales et al., 2014 
100 lM 
10 min 
   5 lM SB203580    
DHPG Long-Evans rats P21-30 Not determined No effect on LTD Increased Blocked LTD Gallagher et al., 
2004 100 lM 
5 min DHPG 
C57/BL6 mice P25-30 Not determined 5 lM SB203580 or 
1 lM SB202190 
Not determined 
Increased 20 lM U0126 or 
50 lM PD98059 
Not determined 
Osterweil et al., 
2010 
100 lM 
5 min 
       
DHPG C57/BL6 mice 4 weeks No effect Not determined Increased Blocked LTD Banko et al., 2006 
50 lM 
5 min 
     20 lM U0126  
 
A variety of signaling pathways have been found to be involved in mGluR-LTD. These include tyrosine dephos-
phorylation (Moult et al. 2002, 2006, 2008) involving striatal-enriched protein phosphatase (STEP) (Zhang et al. 
2008), and the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling cascade 
(Hou and Klann 2004). The most extensively studied pathways have involved the MAPKs. These are a speciﬁc class 
of serine/threonine kinases that respond to extracellular signals such as growth factors, mitogens, and cellular stress (Fig. 
1) and are involved in a diverse array of functions, including proliferation, differentiation, and cell survival. Jun N-
terminal kinases (JNK), p38 MAPK (p38), and extracel- lular signal-regulated kinase 1/2 (ERK1/2) are the three best 
characterized subfamilies of MAPK (Tibbles and Woodgett 1999; Roux and Blenis 2004) and there is evidence to 
suggest that all of these may be involved in mGluR-LTD in the present article, we have therefore focused on the 
hippocampus (Bolshakov et al. 2000; Rush et al. 2002; Curran et al. 2003; Gallagher et al. 2004; Hou and Klann 
2004; Huang et al. 2004; Thomas and Huganir 2004; Banko et al. 2006; Li et al. 2007; Bellone et al. 2008; Moult et 
al.2008; Gladding et al. 2009b; Osterweil et al. 2010; Corre^a and Eales 2012; Seo et al. 2012; Hogg et al. in press). 
 
The role of JNK1 in mGluR-LTD is not clear as although JNK1 knockout mice were found to have impaired mGluR- 
LTD in area CA1 (Li et al. 2007) and pharmacological inhibition of JNK1 prevented mGluR-LTD in the dentate gyrus 
(Curran et al. 2003), there is also contradictory evidence. The pre-incubation of hippocampal slices with JNK1 inhibitors did 
not block synaptically induced  mGluR-LTD in either the CA1 region (Moult et al. 2008) or in the dentate gyrus (Wang et al. 
2007). Also mGluR-LTD can still be induced in hippocampal slices obtained from transgenic mice displaying alterations in 
the C-terminus of JNK1 to prevent its phosphorylation (Seo et al. 2012). Further experiments are needed to clarify the role 
of JNK1 in mGluR-LTD and therefore in the present review we focus on the roles of p38 and ERK1/2 (Table 1). 
 
Since the discovery of mGluR-LTD in the hippocampus, similar forms of synaptic plasticity have been identiﬁed in 
several other brain regions (Anwyl 2006) and have been implicated in a diverse range of physiological and patholog 
ical functions (Table 2; Luscher and Huber 2010). There is currently little evidence for the involvement of MAPKs in 
mGluR-LTD outside of the hippocampus, apart from the role of ERK1/2 in mGluR-LTD in the cerebellum (Ahn et al. 
1999; Kawasaki et al. 1999). Further work is therefore necessary to explore the possible roles for MAPKs in mGluR-
LTD in other brain regions. In the present article, we have focused on the hippocampus, since this is where most 
mechanistic studies have been performed. 
 
The p38 and ERK1/2 cascades regulating mGluR-LTD 
 
p38 MAPK signaling 
Group I mGluRs are G-protein-coupled receptors that couple to the Gaq-containing  heterotrimeric G protein (Fig. 2a). 
Consistent with this DHPG or synaptically induced  mGluR- LTD cannot be induced if Gaq is knocked out (Kleppisch 
et al. 2001). The mechanism by which mGluRs activate p38 is via the release of the Gbc subunit (Huang et al. 2004), 
which triggers a signaling cascade via Rap1 and MKK3/6 to activate p38 (Fig. 2a; Huang et al. 2004). The requirement 
for p38 activation during mGluR-LTD is well-established (Bolshakov et al. 2000; Rush et al. 2002; Huang et al. 2004; 
Moult et al. 2008), however, until recently few p38 substrates had been identiﬁed in mGluR-LTD. 
 
Table 2 
Summary of metabotropic glutamate receptor (mGluR)-LTD induction and expression in different areas of the brain and 
their implications in diseases 
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Fig. 2 Putative model illustrating the mechanism by which the p38 and extracellular signal-regulated kinase 1/2 (ERK1/2) signaling 
cascades regulate mGluR-LTD by either individual (a, b) or comple- mentary pathways (c). (a) Activation of mGluRs by DHPG or 
glutamate stimulates the release of the bc subunit from the Gaq G protein coupled receptor. This leads to the activation of Rap 1 
that activates MKK 3/6 and consequently p38, which binds and phospho- rylates MK2. The activation of MK2 potentially activates 
two MK2- downstream cascades leading to the actin reorganization and endocytosis of AMPARs. (I) MK2 regulates coﬁlin1 
phosphorylation which results in changes in dendritic spine morphology (Eales et al. 2014). The activation of the p38-MK2 cascade 
leads to dephospho- rylation and activation of coﬁlin1 which triggers AMPAR internalization and actin reorganization caused by a 
decrease in the amount of ﬁlamentous actin (F-actin) and an increase in globular actin (G actin). (II) MK2 directly phosphorylates 
p16-Arc one of the subunits of the Arp2/3 complex which regulates actin branching and has been shown to regulate AMPARs 
internalization (Singh et al. 2003; Rocca et al. 2008). (b) The steps linking the binding of mGluRs agonist to ERK1/2 activation have 
not yet been clearly demonstrated. In non-neuronal systems ERK1/2 is activated via Src and Ras (Thandi et al. 2002; Wang et al. 
2007). In neurons mGluR activation results in phospho- rylation of Mnk1 and eukaryotic initiation factors which regulate translation 
of proteins that are known to regulate internalization of AMPAR including Arc/Arg3.1, MAP1B, OPHN1, and striatal-enriched 
protein phosphatase (STEP). (c) Pathways showing how p38 and ERK1/2 can both activate MSK1 and Mnk1 (McCoy et al. 
2005; Chrestensen et al. 2007). Downstream these pathways can lead to changes in the levels of protein translation and 
expression, which results in enhanced AMPAR endocytosis required for mGluR-LTD. 
 
Recently MAP kinase-activated protein kinases 2 and 3 (MK2/3), which are kinases speciﬁcally phosphorylated by 
p38a/b subunits (Clifton et al. 1996; Gaestel 2006; White et al. 2007; Corre^a and Eales 2012), and not by ERK1/2, 
have been found to be required for the induction of mGluR-LTD (Corre^a and Eales 2012; Eales et al. 2014). 
Supporting the involvement of a p38-MK2/3 cascade in mGluR-LTD is the observation that expression of activity- 
regulated cytoskeleton-associated protein (Arc/Arg3.1), a protein required for mGluR-LTD (Waung et al. 2008), is 
signiﬁcantly reduced in  hippocampal tissue from MK2/3 double knockout (DKO) mice at 4 weeks compared to tissue 
obtained from wild-type littermates. Further supporting these ﬁndings is the observation that the impairment of mGluR-
LTD is accompanied by deﬁcits in AMPAR trafﬁcking in hippocampal cultures obtained from MK2/3  DKOs  (Eales  
et al.  2014).  Arc/Arg3.1  has  been shown to control synaptic strength by facilitating endocy- tosis of AMPARs 
(Bramham et al. 2008, 2010; Shepherd and Bear 2011) and is thought to play a role in AMPAR trafﬁcking in 
mGluR-LTD (Park et al. 2008; Waung et al. 2008).  
 
 
(a) (b) (c) 
 
 
It is well established that p38 together with its substrate MK2 are important in the expression of serum response 
element-driven immediate early genes (IEGs) by direct phosphorylation of serum response factor at Ser 103 
(Ronkina et al. 2011; Corre^a and Eales 2012). The ﬁnding that transcriptional activation of the neuronal speciﬁc IEG 
Arc/Arg3.1 is dependent on serum response factor activation in primary cortical neurons may provide a mechanism by 
which p38 regulates transcription of neuronal proteins to regulate synaptic plasticity (Pintchovski et al. 2009; Bram- 
ham et al. 2010; Ronkina et al. 2011). It is important to further investigate whether the p38 cascade has a role in 
activity-dependent transcription of IEGs in neurons indepen- dently of ERK1/2 activation. 
 
In addition to impaired hippocampal mGluR-LTD, MK2/3 DKO mice display distinctive deﬁcits in hippocampal- 
dependent reversal of spatial learning when tested on the Barnes Maze task (Eales et al. 2014). Previous ﬁndings have 
shown that mGluR5 knockout mice display deﬁcits in reversal learning and mGluR-LTD (Xu et al. 2009; Menard and 
Quirion 2012). The extent to which mGluR-LTD signaling, via the p38 MAPK cascade, is involved in reversal learning 
warrants further investigation. 
 
ERK1/2 signaling 
 
The signaling cascade by which mGluRs activate ERK1/2 is less understood compared to that of p38. In non-neuronal 
preparations mGluR signaling can activate ERK1/2 through the Gaq subunit leading to activation of the Src, Ras, and 
MEK1/2 cascade (Fig. 2b; Thandi et al. 2002; Wang et al. 2007). Downstream of ERK1/2 the picture is clearer, as 
signaling proteins that are known to regulate cap-dependent protein translation are activated. These include MAPK- 
interacting protein kinase 1 (Mnk1) and its phosphorylation target, eukaryotic elongation factor 4E (eIF4E; Banko et al. 
2006), providing a route which links protein translation and mGluR activation. Cap-dependent protein translation is a 
highly regulated procedure (see Proud 2007; Joshi and Platanias 2014) and can be divided into three stages: Initiation 
(which is speciﬁcally modulated by ERK1/2- dependent signaling in mGluR-LTD), elongation, and termination. Each 
of these steps is regulated by translation factors that in eukaryotic cells are known as eukaryotic initiation factors (eIFs), 
eukaryotic elongation factors (eEFs), and eukaryotic release factors (eRFs). Rapid modulations in mRNA translation  can  
be  brought  about by changes in the association or activity of these factors. Initiation requires eIFs that form a 
protein complex known as eIF4F. This is composed of a primary scaffolding component, eIF4G, and three other 
proteins eIF4A, eIF4B, and eIF4E. Translation is initiated when the last of these, eIF4E, recognizes the 50 mRNA 
cap, and this allows recruitment of the small ribosome subunit (Gingras et al. 1999). Phosphorylation of eIF4E by 
Mnk1 is thought to regulate protein translation, however, the precise mechanism is not clear (Fig. 2b; Proud 2007; 
Joshi and Platanias 2014). One hypothesis is that phosphorylation of  eIF4E may play a role in the recycling of eIF4E 
from one round of translation initiation to the next, as phosphorylation has been found to reduce the afﬁnity of eIF4E 
for the 50 cap (Scheper and Proud 2002). Phosphorylation of eIF4E has been found to be important for translation 
only under certain conditions, leading to the additional suggestion that phosphorylation of eIF4E may play a role in 
ensuring a subset of mRNAs are expressed (Costa-Mattioli et al. 2009). This hypothesis has been extended to 
suggest that increased translation of  a subset  of proteins  involved in mGluR-LTD, via this mechanism, may play a 
role in regulating the magnitude of mGluR-LTD (Bhakar et al.2012). 
 
Possible points of convergence between p38 ERK1/2 MAPK signaling 
Phosphorylation of Mnk1 at two residues, by either p38 MAPK or ERK1/2, is required for its activation (Fig. 2c; 
Chrestensen et al. 2007). In rats these residues are Thr209/ Thr214 and in mice these residues are Thr197/Thr202 
(Shveygert et al. 2010). As mentioned above, the DHPG- induced activation of Mnk1 is ERK1/2 but not p38 MAPK 
dependent, however, p38 MAPK is involved in maintaining the basal phosphorylation state of Mnk1 in these conditions 
(Banko et al. 2006). Therefore, both p38 and ERK1/2 may regulate Mnk1 activity, possibly in some experimental 
conditions ERK1/2 plays a more signiﬁcant role and in others p38 MAPK. In certain physiological responses p38 MAPK is 
known to induce Mnk1 activation (Fukunaga and Hunter 1997; Waskiewicz et al. 1997; Wu et al. 2013) therefore it is 
plausible that in preparations in which p38 MAPK is involved in mGluR-LTD it may act in part via Mnk1. 
 
Mitogen- and stress-activated protein kinase 1 (MSK1) is also a point of convergence for p38 and ERK1/2 signaling as 
they can both phosphorylate Thr 581 and Ser 360 on the c- terminal docking region to activate MSK1 (Fig. 2c; McCoy 
et al. 2005; Corre^a et al. 2012; Frenguelli and Corre^a 2012). The activation of MSK1 could be instrumental in mGluR- 
LTD through its downstream cascade leading to activity- dependent transcription of Arc/Arg 3.1 (Corre^a et al. 2012) 
which facilitates the endocytosis of AMPARs. However, the role of MSK1 in mGluR-LTD has not been fully investigated 
and further studies are required to establish whether MSK1 is involved in mGluR-LTD. 
 
 
AMPAR trafficking underlying mGluR-LTD via MAPK signaling 
 
It is well established that the endocytosis of AMPARs plays an important role in mGluR-LTD (Carroll et al. 2001; 
Snyder et al. 2001; Xiao et al. 2001; Huang et al. 2004; Moult et al. 2006; Gladding et al. 2009a; Sanderson et al. 
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2011; Eales et al. 2014). Immunoﬂuorescence imaging studies have shown that DHPG exposure results in the loss of 
AMPARs from the surface of cultured hippocampal neurons and the use of an acid stripping protocol reveals a 
corresponding increase in  internalized  AMPARs  (Snyder et al. 2001; Moult et al. 2006). Another study found that a 
minority of puncta disappeared rapidly during perfusion of DHPG, an effect that lasted for at least 30 min and was 
accompanied by an increase in ﬂuorescence intensity in the cell body (Xiao et al. 2001). This study conﬁrms that at least 
part of the effect of DHPG is to promote AMPAR internalization at the post-synaptic membrane. Surface 
biotinylation experiments using acute hippocampal slices have conﬁrmed  that AMPARs are internalized following 
DHPG application (Huang et al. 2004; Moult et al. 2006; Gladding et al. 2009a). 
 
The fact that AMPAR trafﬁcking may not be uniform at all synapses is suggested by live cell imaging of GluA2 tagged 
with the pH-sensitive variant of green ﬂuorescent protein, known as super ecliptic pHluorin (SEP-GluA2). The pH 
sensitivity of SEP results in quenching of its ﬂuorescence when SEP-GluA2 is internalized, as endocytic vesicles are 
acidic. Surprisingly, in primary hippocampal neuronal cultures, DHPG application did not result in an average 
decrease in SEP-GluA2 ﬂuorescence, rather it caused an increase in the variability between puncta (Sanderson et al. 
2011). Thus, the factors that determine the extent to which DHPG induces AMPAR trafﬁcking at individual synapses 
requires further investigation. 
 
MAPK signaling has been found to be directly involved in DHPG-induced internalization of AMPARs as inhibition of 
the p38 cascade prevents AMPAR endocytosis because of its regulation of clathrin-coated vesicle formation (Huang et al. 
2004; Eales et al. 2014). p38 activation increases the formation of a complex that promotes the recycling of the 
small GTPase Rab5, a molecule that is essential for clathrin- coated vesicle formation (Huang et al. 2004). 
 
The emerging role for the p38 substrates MK2 and 3 in mGluR-LTD and AMPAR trafﬁcking, is surprising as 
MK2/3 are classically thought of as being involved in the production and release of inﬂammatory cytokines in 
mammalian cells (Ronkina et al. 2007; Ghasemlou et al. 2010). The deletion of MK2 in mammalian cells reduces the 
production of proinﬂammatory factors, in particular tumor necrosis factor alpha (TNFa) (Kotlyarov et al. 1999). Based 
on this ﬁnding, it has been hypothesized that reduced expression of TNFa may play a role in the block of mGluR- LTD 
that is observed in the MK2/3 DKO mice (Hogg et al. in press). A potential explanation for this is that TNFa is 
necessary for basal synaptic transmission and synaptic scaling (Beattie et al. 2002; Stellwagen and Malenka 2006) and 
has a role in enhancing the exocytosis of AMPARs (Stellwagen et al. 2005). Thus, in MK2/3 DKO mice the 
reduction in mGluR-LTD magnitude may be because of a reduced amount of TNFa at the synapse that is below the 
level required to maintain basal surface AMPAR levels. As the presence of GluA2-containing AMPARs has been 
shown to be necessary for mGluR-LTD (Zhou et al. 2011), this may imply that mGluR-LTD is disrupted in MK2/3 
DKO mice because the number or assortment of AMPARs necessary to trigger mGluR-LTD at synapses is not 
correct. This hypothesis is supported by the observation that the amplitude of AMPAR-mediated miniature excita- tory 
post-synaptic currents (mEPSCs) is reduced in MK2/3 DKO hippocampal neurons (Eales et al. 2014). Further 
investigation is required to determine whether there is a signiﬁcant reduction in the production of TNFa in the 
hippocampus of MK2/3 DKO mice and its potential effect on mGluR-LTD. 
 
The loss of surface AMPARs is blocked by the translation inhibitor cyclohexamide, indicating that this process lies 
downstream of the enhanced protein translation suggested to be involved in mGluR-LTD (Snyder et al. 2001). Indeed, 
many of the proteins that are up-regulated by DHPG exposure play a role in AMPAR endocytosis. These include 
Arc/Arg3.1, the depletion of which causes increased synaptic transmission because of reduced AMPAR internalization 
(Chowdhury et al. 2006; Shepherd et al. 2006) and reduced DHPG-induced internalization of AMPARs (Park et al. 
2008; Waung et al. 2008). Accordingly, Arc/Arg3.1 has been shown to control the trafﬁcking of AMPARs through its 
interaction with clathrin-adaptor protein 2, dynamin, and endophilin (Chowdhury et al.  2006;  Waung  et al.  2008; 
Peebles et al. 2010; Corre^a et al. 2014; Mabb et al. 2014). 
 
Corroborating these ﬁndings is the observation that depletion of Triad3A, which is a protein required for targeting Arc/ 
Arg3.1 protein for degradation, results in enhanced mGluR- dependent synaptic depression whereas over-expression of 
this protein promotes the opposite effect (Mabb et al. 2014). Other proteins up-regulated in mGluR-LTD that play a role 
in AMPAR internalization include oligophrenin-1 (OPHN1), microtubule-associated protein 1B (MAP1B), and STEP 
(Davidkova and Carroll 2007; Zhang et al. 2008; Nadif Kasri et al. 2011). Since ERK1/2 is involved in the regulation 
of translation, it is possible that it regulates the translation of proteins involved in AMPAR internalization. 
 
Dendritic spine morphology in mGluR-LTD 
 
In recent years several reports have suggested a direct link between dendritic spine shrinkage, endocytosis of AMPARs 
and decreases in AMPAR-mediated synaptic transmission in mGluR-LTD. Interestingly, application of agents that prevent 
 
both polymerization and depolymerization of actin have been shown to block mGluR-LTD, but not NMDAR-dependent 
LTD (Xiao et al. 2001; Morishita et al. 2005; Moult et al. 2006). Furthermore, there is a correlation between actin 
reorganization and AMPAR endocytosis after the induction of mGluR-LTD (Vanderklish and Edelman 2002; Zhou et al. 
2011; Eales et al. 2014). At dendritic spines, actin is found in either monomeric globular (G)-actin or ﬁlamentous (F)-actin 
forms, and the shift between these two arrangements promotes actin remodeling and subsequent changes in spine 
morphology (Cingolani et al. 2008). However, the mecha- nism by which activation of group I-mGluRs results in 
dendritic spine morphological changes and reductions in synaptic transmission promoted by AMPAR internalization are 
only recently beginning to emerge. 
 
A key component of the regulation of the actin cytoskeleton during mGluR-LTD is coﬁlin1. The requirement of coﬁlin1 
activity in actin remodeling in multiple forms of synaptic plasticity is well-documented (Hotulainen and Hoogenraad 
2010; Mizuno 2013). Signiﬁcantly, it has been shown that preventing the activation of coﬁlin1 blocks the induction of 
mGluR-LTD (Zhou et al. 2011; Asrar and Jia 2013). Several elements of the upstream regulators of coﬁlin1 during 
mGluR-LTD have been identiﬁed and these include Ras-related C3 botulinum toxin substrate 1 (Rac), p- 21-activated 
kinase, and LIM kinase (Chevy et al. 2015). Recent ﬁndings demonstrated that the p38-MK2 cascade is required to 
regulate coﬁlin1 activity in hippocampal neurons, as inhibition of p38 blocked the DHPG-induced activation of coﬁlin1 
(Eales et al. 2014). Furthermore, dendritic spines of hippocampal neurons obtained from MK2/3 DKO mice displayed 
deﬁcits in spine morphology and impaired DHPG- LTD, a phenotype that was rescued by re-introducing MK2, but not 
MK3, wild-type proteins into hippocampal neurons obtained from MK2/3 DKO mice (Eales et al. 2014). These ﬁndings 
corroborate the suggested mechanism that mGluR- LTD is associated with cytoskeleton reorganization resulting in spine 
morphological changes. 
 
The activation of the mGluR-p38-MK2 pathway could potentially regulate actin remodeling via the activity of the 
actin-related protein 2 and 3 (Arp2/3) proteins complex. The MK2 protein has been shown to interact and 
phosphorylate the p16-Arc subunit of the Arp2/3 complex (Fig. 2a (II); Singh et al. 2003). The mechanism by which 
the Arp2/3 complex mediates actin nucleation, spine morphology, and trafﬁcking of AMPARs in NMDAR- 
dependent LTD has been well-characterized (Rocca et al. 2008, 2013; Henley et al. 2011). However, initial 
experiments have not found a role for Arp2/3 in mGluR-LTD (Rocca et al. 2013). 
 
The interaction between AMPAR subunit GluA2 and the cell adhesion molecule N-cadherin has been found to be 
essential for mGluR-LTD (Zhou et al. 2011). These proteins are both required to induce the coﬁlin1-dependent actin 
reorganization that is necessary for mGluR-LTD. The trafﬁcking of AMPARs is not only required for the 
expression of mGluR-LTD, but AMPARs play a role in the activation of signaling cascades that coordinate the 
processes leading to structural changes. The activation of the ERK1/2 pathway could also orchestrate changes in actin 
reorganization via the STEP-bcatenin-Rac-p-21-activated kinase pathway to regulate coﬁlin1 activity (Asrar and Jia 
2013). 
 
 
The role of MAPK signaling in neurological diseases 
 
Fragile X syndrome and tuberous sclerosis 
 
Fragile X syndrome is the leading cause of inherited mental retardation after Downs syndrome and is associated with 
a fragile site on the X chromosome (at site Xq27.3). The clinical symptoms (reviewed in Gallagher and Hallahan  
2012)  include  severe  intellectual  disability,  reduced executive function, deﬁcits in short-term memory, and deﬁcits 
in attention. As well as these cognitive deﬁcits, patients often suffer from epilepsy, facial dysmorphism, and macro-
orchidism.  This condition is caused by a mutation in the fragile X mental retardation 1  (FMR1) gene which results 
in a CGG triplet repeat being expanded, resulting in silencing of the gene (Verkerk et al. 1991). A detailed description 
of the function of the product of FMR1, FMR protein (FMRP), is beyond the scope of this article (reviewed in 
Darnell and Klann 2013). In summary, FMRP acts as a translational repressor (Laggerbauer et al. 2001; Li et al. 2001; 
Zhang et al. 2001; Aschraﬁ et al. 2005; Qin et al. 2005; Bolduc et al. 2008), targeting a speciﬁc set of mRNAs that 
include 30% of the post- synaptic density proteome (Darnell et al. 2011). Therefore, fragile X syndrome may be the 
result of de-regulated translation of the mRNAs targeted by FMRP and may involve diverse synaptic phenotypes. 
 
mGluR-LTD is of potential relevance to fragile X syndrome, since in FMR1 KO animals the magnitude of 
mGluR-LTD is enhanced (Huber et al. 2002; Till et al. 2015) and it is insensitive to mRNA translation inhibitors 
(Nosyreva and Huber 2006; Till et al. 2015), leading to the theory that fragile X syndrome is related to enhanced 
mGluR-LTD (Bear et al. 2004). This enhanced mGluR-LTD may be because of the elevated expression of proteins (Qin 
et al. 2005), including Arc/Arg3.1 and MAP1B (Zalfa et al. 2003; Darnell et al. 2011), as a result of the absence of 
regulation by FMRP. 
 
ERK1/2 signaling may play a crucial role in the patho- physiology of this disease since the elevated protein expression 
in FMR1 KO mice is normalized to wild-type levels by ERK1/2 inhibition (Osterweil et al. 2010). The basal 
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phosphorylation state of ERK1/2 was found to be unaltered, leading the authors to suggest that the elevated protein 
expression levels may be because of greater sensitivity of the translation machinery to ERK1/2 signaling (Osterweil et al. 
2010). ERK1/2 is also a target of FMRP (Darnell et al. 2011), therefore it may be that the protein synthesis 
machinery is responding to elevated levels of ERK1/2, which may result from the loss of translational repression by 
FMRP. p38 MAPK phosphorylation was found to be decreased in FMR1 KO mice (Osterweil et al. 2010) and it was 
suggested that this may be a compensatory down- regulation in response to elevated protein synthesis. This may 
represent another area of cross talk between p38 MAPK and ERK1/2 signaling. 
 
Regulating mGluR5 function has been explored as a potential strategy to treat fragile X syndrome (D€olen et al. 2010). 
However, clinical trials to investigate drugs acting at mGluR5 have not been successful to date. A drug currently 
approved to treat hypercholesterolemia, Lovestatin, is suggested to be able to correct enhanced  mGluR-LTD as well as 
epileptiform activity in FMR1 KO mice via inhibition of the Ras-ERK1/2 pathway (Osterweil et al. 2013). Therefore, 
currently available drugs may potentially be utilized to treat this condition via this mechanism. It is worth noting that 
elevated protein translation observed in FMRP KO mice can be rescued to basal levels by inhibiting the mTOR cascade 
(Sharma et al. 2010). Thus, a variety of different potential therapeutic targets downstream of  mGluRs can be considered 
for the treatment of fragile X syndrome. 
 
There are also links between fragile X syndrome and other conditions; in particular autism spectrum disorders (ASD) are 
over represented in fragile X syndrome patients (Gallagher and Hallahan 2012). It is therefore of interest that animal 
models of another genetic condition that is linked with ASD, tuberous sclerosis (Bolton et al. 2002) also exhibit altered 
mGluR-LTD. However, in the two tuberous sclerosis animal models studied to date, the magnitude of mGluR-LTD is 
reduced rather than increased in the hippocampus (Auerbach et al. 2011; Chevere-Torres et al. 2012). This disease is also 
the result of deregulation of protein translation, and is because of the loss of either hamartin (TSC1) or tuberin 
(TSC2). The disease was modeled in these studies using either heterozygous TSC2 knockouts (Auerbach et al. 2011) 
or by introducing a loss of function mutation into TSC2 (Chevere-Torres et al. 2012). Enhanced ERK1/2 activation 
was detected in the second of these models, and the deﬁcit in mGluR-LTD was prevented by ERK1/2 inhibition, suggest- 
ing that enhanced ERK1/2 signaling may play a role in the pathophysiology of this disease (Chevere-Torres et al. 2012). 
In the ﬁrst model (TSC2 knockouts) the decreased mGluR- LTD was prevented by rapamycin, an mTOR inhibitor 
(Auerbach et al. 2011), again pointing to a balance in MAPK and mTOR signaling which may be driven in different 
directions depending on the experimental conditions. 
 
In summary, in ASD-related models of disease ERK1/2 inhibition can reduce aberrantly enhanced mGluR-LTD 
(Osterweil et al. 2010, 2013) and can increase pathologically reduced mGluR-LTD (Chevere-Torres et al. 2012). These 
results may indicate that an optimal level of ERK1/2 activation is necessary for the correct expression of mGluR-LTD 
and associated cognitive function. 
 
Alzheimer’s disease 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that causes cognitive impairments. Atrophy of the 
hippocampus is seen at an early stage of the disease (Sabuncu et al. 2012) and hippocampal volume continues to 
decrease as the disease progresses (Simi'c et al. 1997; Sabuncu  et al. 2012). The neuropathology of AD is 
characterized by the presence of extracellular senile plaques composed of amyloid beta (Ab) and intracellular 
neuroﬁbrillary tangles formed from hyperphosphorylated  tau (Spire- Jones and Hyman 2014). The investigation of 
hippocampal mGluR-LTD in Alzheimer’s disease is limited compared to other forms of synaptic plasticity, such as 
LTP (Klyubin et al. 2012). However, it is vital to further examine mGluR- LTD in this disease as the signaling pathways 
associated with mGluR-LTD have been implicated in the generation of Ab, hyperphosphorylation of tau and loss of 
synapses, which are all involved in the pathology of AD. The potential importance of mGluR-LTD in Alzheimer’s is 
supported by the observation that deletion or inhibition of mGluR5 rescued spatial learning and reduced Ab plaque 
load in an AD mouse model (Um et al. 2013; Hamilton et al. 2014). 
 
Exogenous application of soluble Ab to hippocampal slices enhances  LTD produced by  subthreshold low  frequency 
stimulation, whereas in control conditions the same stimulation protocol is ineffective at inducing LTD. The Ab- 
mediated enhancement of subthreshold LTD is blocked by the application of a group I-mGluR inhibitor, suggesting it 
may share mechanisms with mGluR-LTD (Shankar et al. 2008; Li et al. 2009). In the dentate gyrus Ab also facilitates 
mGluR-LTD and importantly this is dependent on the activation of p38 (Chen et al. 2013). Also, the prolonged 
exposure of cultured hippocampal slices to Ab occludes mGluR-LTD and the proposed mechanism underlying this 
change is that Ab exposure initially promotes the phosphorylation and endocytosis of AMPARs which leads to 
occluded mGluR-LTD at the later time point (Hsieh et al. 2006). This Ab-mediated internalization of AMPARs is 
hypothesized to contribute to the loss of synapses that is observed in Alzheimer’s disease (Shankar and Walsh 2009). 
 
Supporting this hypothesis is the ﬁnding that expression of an AMPAR mutant that prevents the mGluR-LTD-dependent 
endocytosis of AMPAR also prevents the morphological changes and loss of dendritic spines observed after prolonged 
Ab exposure (Hsieh et al. 2006). The proteins that mediate mGluR-dependent activation of the MAPK cascade leading 
to AMPAR internalization could therefore be potential therapeutic targets in Alzheimer’s disease. 
 
Other signaling molecules that are involved in mGluR- LTD have been implicated in Alzheimer’s disease. These 
include Arc/Arg3.1 (Dorostkar and Herms 2012), which is required for activity-dependent production of Ab (Wu et al. 
2011). The deletion of Arc/Arg3.1 reduces Ab load in AD transgenic mice and this effect is because Arc/Arg3.1 
regulates the trafﬁcking of amyloid precursor protein as well as directly binding to presenilin-1, which is a c secretase 
required for the production of Ab. It is hypothesized that Arc/Arg3.1 plays a role in the activity driven production of 
Ab because it increases the association between amyloid precursor protein and presenilin-1 (Wu et al. 2011). 
 
The activation of the MAPK pathways, especially the p38 cascade, have strong links to neurodegeneration (Munoz and 
Ammit 2010; Corre^a and Eales 2012). Ab exposure stimulates the activation of the p38 pathway in vitro (Pyo et al. 
1998; Jin et al. 2005; Corre^a and Eales 2012). In addition to this p38 is up-regulated in human AD brains (Hensley et 
al.1999) and in an AD mouse model (Savage et al. 2002). The role of ERK1/2 in Alzheimer’s disease is not yet as clear 
and there have been reports of it being both up-regulated (Pyo et al. 1998; Pei et al. 2002) and down-regulated by Ab 
exposure (Jin et al. 2005). The inhibition of ERK1/2 or p38 has had success in reducing cognitive impairments in AD 
model mice (Munoz et al. 2007; Ashabi et al. 2012). This could be because the inhibition of p38 prevents the increased 
endocytosis of AMPARs on exposure of endogenous Ab and therefore rescues the impairment of LTP (Wang et al. 2004; 
Nomura et al. 2012). The over-activation of this pathway is signiﬁcant as p38 activation has been shown to play a role in 
the hyperphosporylation of tau, which results in neuroﬁbrillary tangles, a hall mark of Alzheimer’s (Lauretti and Pratic'o 
2015). Preventing the up-regulation of MAPK pathways could be a therapeutic strategy to delay the cognitive 
impairments observed in AD. 
 
The increased production of Ab stimulates the activation and proliferation of microglia in Alzheimer’s disease (Meda et 
al. 1995) which in turn causes an increase in the release of neuroinﬂammatory factors such as TNFa (Combs et al. 2001). 
The release of TNFa has been shown to enhance the exocytosis of AMPARs (Stellwagen et al. 2005). Therefore, 
hypothetically the increase in TNFa production during Alzheimer’s could be linked to AMPAR internalization possibly 
via mGluR–LTD (Hogg et al. in press). The inhibition of the p38 cascade prevents the Ab-mediated increase in the 
production of inﬂammatory factors and this could be another beneﬁcial effect of therapeutically targeting p38 
(Bachstetter et al. 2011). Although direct evidence for proinﬂammatory factors regulating mGluR-LTD is lacking, there 
are recent studies that highlight neuroinﬂammation as an interesting area to develop therapeutic intervention in 
cognitive decline in Alzheimer’s (Tobinick et al. 2006; Shi et al. 2011). 
 
Until recently speciﬁc drugs to target single isoforms of MAPKs were not available but a small peptide inhibitor of 
p38a has  now been developed, MW01-18-150SRM, and administration of this peptide rescued the spatial memory 
deﬁcits seen in a transgenic Alzheimer’s disease model (Roy et al. 2015). There have also been advances in the 
development of speciﬁc MK2 inhibitors which may also be a good target for the inhibition of the p38 cascade, as 
targeting proteins downstream of p38 offer the advantage of reducing unwanted side effects by inhibiting only one and not 
all the p38 effector proteins (Duraisamy et al. 2008). The targeting of mGluR5 has also been proposed as a possible 
therapeutic target in AD (Kumar et al. 2015). 
 
Final remarks 
 
In the last decade considerable progress has been made in understanding the role of MAPK cascades in regulating the 
induction and maintenance of mGluR-LTD. Proteins down- stream  of  mGluR-MAPK  activation  are likely  to  play  a 
critical and speciﬁc role in mGluR-LTD and its associated forms of learning and memory. Therefore, the 
characterization of these effectors may reveal novel therapeutic targets to slow down cognitive impairments observed in 
natural aging and diseases. To develop novel and speciﬁc targets with reduced side effects, further fundamental 
research is required to map the precise proteins downstream of the individual MAPK cascades as well as the potential 
cross talk between these cascades as they orchestrate mGluR-LTD (Fig. 2). 
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mGluR-LTD is a form of synaptic plasticity that impacts on memory formation. In the hippocampus mitogen-activated 
protein kinases (MAPKs) have been found to be important in mGluR-LTD. In this 60th anniversary special issue article, we 
review the independent and complementary roles of two classes of MAPK, p38 and ERK1/2 and link this to the aberrant 
mGluR-LTD that has an important role in diseases. 
 
Abbreviations used: (F)-actin, ﬁlamentous actin; (G)-actin, globular actin; AD, Alzheimer’s disease; AMPAR, a-amino-
3-hydroxy-5-methyl- 4-isoxazolepropionic acid receptors; APP, amyloid precursor protein; Arc/Arg3.1, activity-
regulated cytoskeleton associated protein; Arp2/3, actin related protein 2 and 3; ASD, autism spectrum disorders; Ab, 
amyloid beta; DHPG, (RS)- or (S)-3,5-dihydroxyphenylglycine; DKO, double knockout; eEFs, eukaryotic elongation 
factors; eIFs, eukaryotic initiation factors; eRFs, eukaryotic release factors; ERK1/2, extracellular 
signal-regulated kinase 1/2; FMR1, fragile mental retardation 1; FMRP, fragile mental retardation protein; GFP, green 
ﬂuorescent protein; IEGs, immediate early genes; JNK, Jun N-terminal kinases; KO, knockout; LIMK, LIM kinase; 
LTD, long-term depression; LTP, long-term potentiation; MAP1B, microtubule-associated protein 1B; MAPK, 
mitogen activated protein kinase; mEPSCs, miniature excitatory postsy- naptic currents; mGluR, metabotropic glutamate 
receptor; MK2/3, mitogen-activated protein kinase-activated protein kinases 2 and 3; Mnk1, MAPK interacting protein 
kinase 1; MSK1, mitogen and stress activated protein kinase 1; mTOR, mammalian target of rapamycin; NMDAR, N-
methyl-D-aspartate receptors; OPHN1, oligophrenin-1; PAK, p-21 activated kinase; PP-LFS, paired-pulse low 
frequency stimulation; Rac1, Ras-related C3 botulinum toxin substrate 1; SEP, super-ecliptic pHluorin; SRE, serum-
response-element; SRF, serum response factor; STEP, striatal enriched protein phosphatase; TNFa, tumor necrosis 
factor alpha; TSC1/2, tuberous sclerosis 1/2. 
 
